Latest filingSep 16, 2026Most recent Form 4
INM
InMed Pharmaceuticals Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/17 to 09/17. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$11.8M3 buys
Total selling$00 sells
Net open-market+$11.8M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period3transactions
- P · Open-market buys · dominant3 · 100%
Activity by reported role
A joint filing can contribute to multiple roles3transactions
- 10% owner · dominant3 · 100%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeSchneeberger DanielCommon Shares · Indirect · See Footnote
892,101Sep 16, 2026
ADAR1 Capital Management, LLCCommon Shares · Indirect · See Footnote
892,101Sep 16, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 17 → Sep 17
LessMore
Top insiders
By absolute net value across the selected period- AL+$118.1k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
No filing-only signal badges matched this period.
INM transaction history
Filters apply within this company and selected period by defaultLatest insider transactions
Form 4 filings from last month. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #222862 | INM | ADAR1 Capital Management, LLC | 10% | buy | 8.34k | $1.07M | P | 09/16 | 09/16 |
| #222861 | INM | ADAR1 Capital Management, LLC | 10% | buy | 54.2k | $7.04M | P | 09/16 | 09/15 |
| #222860 | INM | ADAR1 Capital Management, LLC | 10% | buy | 28.5k | $3.68M | P | 09/16 | 09/14 |
InMed Pharmaceuticals Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at InMed Pharmaceuticals Inc.?
ADAR1 Capital Management, LLC, Schneeberger Daniel.
When was the latest reported open-market purchase?
ADAR1 Capital Management, LLC reported a buy on Sep 16, 2026 valued at $1.07M. Read the SEC filing.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $118,076.02. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.